Limitations, agreements, and source contact

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors · Source last updated 2025-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

kpraghav@mdanderson.org

organization

The University of Texas MD Anderson Cancer Center

phone

(917) 733-0356

title

Dr. Kanwal Raghav

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice